LEADER 01500nam  2200361   450 
001 9910688274403321
005 20230704203500.0
035   $a(CKB)5850000000050400
035   $a(NjHacI)995850000000050400
035   $a(EXLCZ)995850000000050400
100   $a20230704d2022      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aHepatitis B /$fLuis Rodrigo, editor
210  1$aLondon :$cIntechOpen,$d2022.
215   $a1 online resource (126 pages)
311   $a1-80355-008-2 
330   $aCurrent pharmacologic therapies for chronic hepatitis B virus (HBV) infection allow viral suppression and normalization of the liver enzyme alanine aminotransferase (ALT) and prevent liver disease from progressing. The currently available antiviral therapies very rarely lead to a functional cure. Thus, the future of a cure for HBV lies in triple combination therapies with concerted action on replication inhibition, antigen reduction, and immune stimulation. This book reviews the mechanisms and pathogenesis of HBV, as well as discusses current and potential future treatments.
606   $aHepatoma
606   $aLiver$xTumors
615  0$aHepatoma.
615  0$aLiver$xTumors.
676   $a616.99436
702   $aRodrigo$b Luis
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910688274403321
996   $aHepatitis B$92902988
997   $aUNINA